Another listed company is planning a change in control rights! On the evening of December 26, Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. (600721) announced that it had received a notification from its controlling shareholders and actual controllers, Mi Zaiqi, Mi Enhua, and Yang Xiaoling, on December 26, 2025. Mi Zaiqi, Mi Enhua, and Yang Xiaoling are currently planning a share transfer agreement, which may lead to a change in the company's control.
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. stated that, given the ongoing negotiations for this equity transfer agreement and the associated uncertainties, the company has applied for a trading halt to ensure fair information disclosure, protect investor interests, and prevent abnormal stock price fluctuations. In accordance with relevant regulations, including the Shanghai Stock Exchange Listing Rules, the company's shares will be suspended from trading starting Monday, December 29, 2025, with an expected halt not exceeding two trading days.
During the suspension period, the company will strictly fulfill its information disclosure obligations based on the progress of the aforementioned matters, following relevant laws and regulations. Once the matters are finalized, the company will promptly release relevant announcements and apply for the resumption of trading. The company emphasized that these planned significant matters still carry uncertainty.
Public information shows that Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. is registered in Wujiaqu City, Xinjiang. Its main business covers early-stage drug discovery and screening, drug CMC development, clinical trials, registration applications, BE/PK biological sample analysis and pharmaceutical testing services, clinical SMO and data services, MAH services, and API and intermediate technical services. It provides clients with comprehensive, one-stop outsourcing services and technical achievement transformation from drug discovery and pharmaceutical CMC development to clinical trials and registration.
The company's business model is based on pharmaceutical research and clinical trials, offering integrated services including technology development, technology transfer, clinical trials, and registration applications to meet diverse and personalized technical requirements of clients, thereby generating corporate revenue.
For the first three quarters of 2025, Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. reported revenue of 298.6 million yuan, a year-on-year increase of 2.74%, and a net profit of 32.67 million yuan, a significant increase of 36.41% compared to the same period last year.
On December 25 and December 26, the company's stock price closed up 6.54% and 5.88% respectively. As of the close on December 26, the share price was 12.24 yuan per share, with a total market capitalization of 4.707 billion yuan.
Comments